By Chris Wack

 

Abbott Laboratories received clearance from the U.S. Food and Drug Administration for its Alinity m STI Assay, the company said Wednesday.

The test simultaneously detects and differentiates four common sexually transmitted infections--Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium--and requires one swab sample or a urine sample collected in a healthcare setting by either a clinician or by the patient, the company said.

The test runs on Abbott's Alinity m system, a high-volume laboratory molecular instrument.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 04, 2022 09:27 ET (13:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Abbott Laboratories
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Abbott Laboratories